|
| |
ImmunoGenImmunoGen, Inc. develops pharmaceuticals, primarily for the treatment of cancer. The Company's product candidates arecalled tumor-activated prodrugs ("TAPs") and are based on its proprietary immunoconjugate technology platform. Unlike conventional chemotherapeutic agents, TAPs are intended to deliver potent chemotherapy specifically to a tumor. Each TAP immunoconjugate comprises a small-molecule drug which has been chemically linked to a monoclonal antibody. The small-molecule drugs are highly potent cell-killing (cytotoxic) agents, while the monoclonal antibodies identify and bind to tumor cells. An important characteristic of TAPs is that they remain inactive and nontoxic until they bind to the surface of a tumor cell, after which their full cytotoxicity is restored.
| Contact Details: |
| 128 Sidney Street |
| Cambridge |
| MA |
| 02139 |
| United States of America |
| Tel: | (617) 995-2500 |
| Fax: | 617-995-2510 |
| Email: | |
| WWW: | www.immunogen.com/
|
|
Loading...
|
Recent Publications by ImmunoGen: |  |
Tumor Delivery and In Vivo Processing of Disulfide-Linked and Thioether-Linked Antibody-Maytansinoid Conjugates.
Antibody-drug conjugates (ADCs) are designed to eradicate cancer cells... | 7th November, 2009
| ImmunoGen, Inc., 830 Winter Street, Waltham, Massachusetts 02451.
| Bioconjug Chem. 2009 Nov 5.
DOI Direct Link |
Antibody-cytotoxic agent conjugates: preparation and characterization.
Conjugates of antibodies with cytotoxic agents offer a targeted... | 23rd April, 2009
| ImmunoGen Inc., Waltham, MA, USA.
| Methods Mol Biol. 2009;525:445-67, xiv.
DOI Direct Link |
Targeted cancer therapy: conferring specificity to cytotoxic drugs.
The therapeutic activity of most anticancer drugs in clinical use is... | 29th May, 2008
| ImmunoGen, Inc., 128 Sidney Street, Cambridge, Massachusetts 02139, USA.
| Acc Chem Res. 2008 Jan;41(1):98-107. Epub 2007 Aug 18.
DOI Direct Link |
Cell killing by antibody-drug conjugates.
Antibody-drug conjugates (ADCs) are designed to specifically bind to and... | 10th November, 2007
| ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.
| Cancer Lett. 2007 Oct 8;255(2):232-40. Epub 2007 Jun 5.
DOI Direct Link |
The rabies peripheral challenge test: more accurate determination of vaccine potency.
The National Institutes of Health (NIH) rabies vaccine potency test is... | 5th January, 2007
| ImmunoGen Inc., 128 Sidney Street, Cambridge, MA 02139-4239, USA.
| Vaccine. 2006 Nov 30;24(49-50):7115-23. Epub 2006 Jul 21.
DOI Direct Link |
→View more ImmunoGen research publications. |
Press Releases on ImmunoGen:
|
 |
| ThromboGenics and BioInvent Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients With Advanced Solid Tumours |
16th November, 2009 |
|
LEUVEN, Belgium and LUND, Sweden, November 16 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR) and BioInvent
International AB (OMXS: BINV) today announced positive results from a Phase I
|
| Reportlinker Adds Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment |
26th October, 2009 |
Reportlinker |
-- A focus on "engineered" antibodies
Monoclonal Antibodies: Pipeline Analysis and Competitive Assessment reviews the broad drug development effort that is focused on bringing
|
| New Report Just Published: World Multiple Myeloma Therapeutics Market Report |
7th July, 2009 |
Reportlinker |
NEW YORK, July 7 /PRNewswire/ -- Reportlinker.com just added a new market research report to its catalogue.
World Multiple Myeloma Therapeutics Market
http://www.reportlinker.com/p0119496/World
|
| MedPredict Publishes Two New Reports Providing Expert Analysis of Malignant Hematology Drug Development |
23rd January, 2009 |
MedPredict |
SCOTTSDALE, Ariz., Jan. 23 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published two new reports providing
|
| Bioinvent's Candidate Drug Against Hiv/Aids Approved To Enter Clinical
|
1st May, 2005 |
Bioinvent |
Bioinvent's
Candidate Drug Against Hiv/Aids Approved To Enter Clinical Trials In UK
Lund,
Sweden: 18 May 2005 -
BioInvent (SAX: BINV) has
obtained approval from the
|
BioPortfolio Ltd provides targeted e-mail address lists for the life science sector - we can enable you to contact around 18 individuals from ImmunoGen using this service.  Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 439 times since April 2007, the link to the organisation's website has been followed 74 times Recent Search Terms used to find this page: immunogen news | immunogen e-mail address | vaccine companies in ma usa | linking cytotoxic agents to monoclonal antibodies service contracts | immunogen email contact | maytansine solubility | immunogen contact | immunogen patents | immunogen | immunogen | . Search for more companies in Cambridge Search for more companies in MA This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for ImmunoGen |
